PUBLISHER: DelveInsight | PRODUCT CODE: 1226652
PUBLISHER: DelveInsight | PRODUCT CODE: 1226652
"SMYRAF Drug Insight and Market Forecast - 2032" report provides comprehensive insights about SMYRAF for Rheumatoid Arthritis in Japan. A detailed picture of the SMYRAF for Rheumatoid Arthritis in Japan for the study period 2019-2032 is provided in this report along with a detailed description of the SMYRAF for Rheumatoid Arthritis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SMYRAF market forecast, analysis for Rheumatoid Arthritis in Japan, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Rheumatoid Arthritis.
Peficitinib (SMYRAF) is an orally bioavailable, once-daily JAK inhibitor, developed for the treatment of patients with Rheumatoid Arthritis (RA) (including the prevention of structural injury of joints) who have had an inadequate response to DMARDs, including MTX. Peficitinib is a pan-JAK inhibitor that inhibits JAK1, JAK2, JAK3, and TYK2. Compared with other JAK inhibitors, Peficitinib is moderately selective for JAK3 (over JAK1, JAK2, and TYK2). Less potent inhibition of JAK2 may explain why reduced hemoglobin levels, potentially attributable to JAK2 inhibition, have not been observed with Peficitinib.
The recommended dosage of Peficitinib in Japan is 150 mg once daily after meals. The dosage can be 100 mg once daily, depending on the patient's condition. Peficitinib is contraindicated in patients with severe liver dysfunction, and the dosage should be 50 mg once daily in those with moderate liver dysfunction.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
SMYRAF Analytical Perspective by DelveInsight
This report provides a detailed market assessment of SMYRAF in Rheumatoid Arthritis in Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of SMYRAF in Rheumatoid Arthritis covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions